Company news
Equillium, Inc. (NASDAQ:EQ) news
Equillium, Inc. news releases on 6ix. Latest, Jan 4, 2022: Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
Press releases — page 3
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
January 3, 2022
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
December 12, 2021
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
November 9, 2021
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
November 4, 2021
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
November 3, 2021
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
November 1, 2021
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
October 17, 2021
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
September 29, 2021
Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis
August 10, 2021
Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update
August 9, 2021
Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA
July 11, 2021
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
June 10, 2021
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
May 12, 2021
Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
April 26, 2021
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
March 29, 2021
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
March 23, 2021
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation
March 14, 2021
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
February 8, 2021
Equillium Announces Closing of $30 Million Registered Direct Offering
February 4, 2021
Equillium Announces Pricing of $30 Million Registered Direct Offering
February 3, 2021
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
January 21, 2021
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of Research & Development and Chief Medical Officer
December 20, 2020
Equillium Provides Itolizumab COVID-19 Program Update
November 24, 2020
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
November 9, 2020
Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease
November 5, 2020
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
October 28, 2020
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
September 14, 2020
Equillium Announces Closing of Public Offering of Common Stock
August 17, 2020
Equillium Announces Proposed Public Offering of Common Stock
August 12, 2020
Equillium Announces Pricing of Public Offering of Common Stock
August 12, 2020
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
August 11, 2020
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
August 9, 2020
Equillium Reports First Quarter 2020 Financial Results
May 12, 2020
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
March 29, 2020
Equillium Strengthens Leadership Team with Key Appointments
February 26, 2020
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
December 8, 2019
Equillium Announces Leadership Updates
November 11, 2019
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
September 30, 2019